<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11558">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01857206</url>
  </required_header>
  <id_info>
    <org_study_id>V58_31</org_study_id>
    <secondary_id>U1111-1139-9440</secondary_id>
    <nct_id>NCT01857206</nct_id>
  </id_info>
  <brief_title>Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age</brief_title>
  <official_title>A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (FluvirinÂ®), in Healthy Children and Adolescents 4 to 17 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>Philippines : Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>New Zealand: Medsafe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents
      4 to 17 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Proportion of subjects reporting solicited local and systemic Adverse Events</measure>
    <time_frame>Day 1 to Day 7 for previously and not-previously vaccinated  subjects and Day 29 to Day 35 for not-previously vaccinated subjects</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects reporting  Unsolicited Adverse Events</measure>
    <time_frame>Day 1 to Day 28 for previously and not-previously vaccinated subjects and Day 29 to Day 49 for not previously vaccinated subjects</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects reporting Medically attended Adverse Events,, Adverse events leading to vaccine/ study withdrawl, new onset of chronic diseases and Serious Adverse Events</measure>
    <time_frame>Day 1 to Day 183 for previously vaccinated subjects and Day 213 for not-previously vaccinated subjects</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2055</enrollment>
  <condition>Influenza</condition>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>TIVc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 0.5 mL dose of vaccine administered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 0.5 mL dose of vaccine administered intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mammalian cell based flu vaccine</intervention_name>
    <arm_group_label>TIVc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg based flu vaccine</intervention_name>
    <arm_group_label>TIVf</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Healthy subjects 4-17 years of age

        Exclusion Criteria:

          -  Subjects who are not healthy,

          -  Subjects who are pregnant or breast feeding,

          -  Subjects with a history of severe allergic reaction or allergic to any of the vaccine
             components.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>320, Novartis Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>312, Novartis Investigational Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>313, Novartis Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>305, Novartis Investigational Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>301, Novartis Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302, Novartis Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>311, Novartis Investigational Site</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>308, Novartis Investigational Site</name>
      <address>
        <city>Winston-salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>317, Novartis Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>309, Novartis Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>314, Novartis Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>319, Novartis Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>310, Novartis Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>318, Novartis Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>315, Novartis Investigational Site</name>
      <address>
        <city>Salt Lake</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>304, Novartis Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>306, Novartis Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303, Novartis Investigational Site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>102, Novartis Investigational Site</name>
      <address>
        <city>Yamba</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>100, Novartis Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108, Novartis Investigational Site</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107, Novartis Investigational Site</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104, Novartis Investigational Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103, Novartis Investigational Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105, Novartis Investigational Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>151, Novartis Investigational Site</name>
      <address>
        <city>Takapuna</city>
        <state>Auckland</state>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>150, Novartis Investigational Site</name>
      <address>
        <city>Beckenham</city>
        <state>Christchurch</state>
        <zip>8024</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>251, Novartis Investigational Site</name>
      <address>
        <city>Muntinlupa City</city>
        <state>Alabang</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>250, Novartis Investigational Site</name>
      <address>
        <city>Muntinlupa City</city>
        <state>Alabang</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>254, Novartis Investigational Site</name>
      <address>
        <city>Muntinlupa City</city>
        <state>Alabang</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>253, Novartis Investigational Site</name>
      <address>
        <city>Manila</city>
        <state>Ermita</state>
        <zip>1001</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>252, Novartis Investigation Site</name>
      <address>
        <city>Manila</city>
        <state>Sampaloc</state>
        <zip>1001</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>201, Novartis Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>Muang</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>200, Novartis Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <state>Rajathevi</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202, Novartis Investigational Site</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Siriraj</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>children and adolescents</keyword>
  <keyword>trivalent vaccine</keyword>
  <keyword>cell culture</keyword>
  <keyword>embryonated chicken eggs</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
